BiotechTube

HTX-034 + HTX-034 + Bupivacaine HCl

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bunions

Conditions

Bunions

Trial Timeline

May 18, 2020 → Aug 3, 2021

NCT ID
NCT04398329

About HTX-034 + HTX-034 + Bupivacaine HCl

HTX-034 + HTX-034 + Bupivacaine HCl is a phase 1/2 stage product being developed by Heron Therapeutics for Bunions. The current trial status is completed. This product is registered under clinical trial identifier NCT04398329. Target conditions include Bunions.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04398329Phase 1/2Completed

Other Products from Heron Therapeutics

SUSTOLApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine HClApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionApproved
77